One of the abstracts to be presented at ASCO this year gives us some insight into risk for and time to death among men with non-metastatic but castration-resistant prostate cancer (nmCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, death, metastasis, nmCRPC, nonmetastatic, risk, time | 20 Comments »
A new review article in the journal Oncology provides an excellent and relatively brief overview of the current options and recommendations for treatment of men with non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, Management, nmCRPC, non-metastatic, Treatment | 5 Comments »
According to a media release issued by Astellas Pharma and Medivation earlier today, the companies have initiated a new Phase III clinical trial to investigate the efficacy and safety of enzalutamide in the management of non-metastatic (TxNxM0), castration-resistant prostate cancer (nmCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, enzalutamide, nmCRPC, non-metastatic, PROSPER | 2 Comments »
Our two most recent CureTalk on Prostate Cancer events (in April and May this year) have featured Dr. Paul Schellhammer (who is both a patient and a former President of the AUA) and focused on the idea of "Living well with prostate cancer".
For access to the full list of CureTalks on Prostate Cancer, please click here.
News and information provided on this site should not be used for diagnosing or treating any health problem or disease.
The "New" Prostate Cancer InfoLink is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.
Blog at WordPress.com. WP Designer.
